DLGAP4

Summary

DLGAP4 (DLG associated protein 4, HGNC:24476) is a protein-coding gene on chromosome 20q11.23, encoding Disks large-associated protein 4 (Q9Y2H0). May play a role in the molecular organization of synapses and neuronal cell signaling.

The product of this gene is a membrane-associated guanylate kinase found at the postsynaptic density in neuronal cells. It is a signaling molecule that can interact with potassium channels and receptors, as well as other signaling molecules. The protein encoded by this gene can interact with PSD-95 through its guanylate kinase domain and may be involved in clustering PSD-95 in the postsynaptic density region. The encoded protein is one of at least four similar proteins that have been found. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 22839 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 145 total
• MANE Select transcript: NM_001365621

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24476
Approved symbol	DLGAP4
Name	DLG associated protein 4
Location	20q11.23
Locus type	gene with protein product
Status	Approved
Aliases	DAP4, KIAA0964, SAPAP4
Ensembl gene	ENSG00000080845
Ensembl biotype	protein_coding
OMIM	616191
Entrez	22839

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 11 protein_coding, 6 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000339266, ENST00000340491, ENST00000373907, ENST00000373913, ENST00000475894, ENST00000477195, ENST00000478910, ENST00000479220, ENST00000479951, ENST00000482037, ENST00000482872, ENST00000489701, ENST00000491207, ENST00000495241, ENST00000497862, ENST00000917065, ENST00000917066, ENST00000953306

RefSeq mRNA: 14 — MANE Select: NM_001365621 NM_001042486, NM_001365621, NM_001388257, NM_001388260, NM_001388262, NM_001388265, NM_001388268, NM_001388271, NM_001388274, NM_001388275, NM_001388277, NM_001388278, NM_014902, NM_183006

CCDS: CCDS13274, CCDS13275, CCDS93034

Canonical transcript exons

ENST00000339266 — 13 exons

Exon	Start	End
ENSE00000520577	36436109	36436350
ENSE00000661800	36446697	36446937
ENSE00000661801	36442727	36442777
ENSE00000661802	36439754	36439868
ENSE00001146778	36367045	36367275
ENSE00001146805	36431646	36432716
ENSE00003471293	36499588	36499676
ENSE00003476410	36526813	36528633
ENSE00003488351	36500199	36500611
ENSE00003641429	36525851	36526006
ENSE00003664890	36524250	36524341
ENSE00003684659	36496705	36497066
ENSE00003734271	36306339	36306512

Expression profiles

Bgee: expression breadth ubiquitous, 270 present calls, max score 98.48.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 59.6489 / max 495.7955, expressed in 1822 samples.

FANTOM5 promoters (18 alternative TSS)

Promoter ID	TPM avg	Samples expressed
184395	26.9486	1817
184397	19.8759	1743
184396	4.3597	1535
184391	1.5158	191
184404	1.1021	686
184400	0.8474	545
184394	0.8063	513
184401	0.6952	428
184403	0.5622	303
184406	0.5152	287

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	98.48	gold quality
ganglionic eminence	UBERON:0004023	97.66	gold quality
ascending aorta	UBERON:0001496	97.58	gold quality
thoracic aorta	UBERON:0001515	97.55	gold quality
skin of leg	UBERON:0001511	97.47	gold quality
aorta	UBERON:0000947	97.31	gold quality
right coronary artery	UBERON:0001625	97.29	gold quality
descending thoracic aorta	UBERON:0002345	97.26	gold quality
popliteal artery	UBERON:0002250	97.24	gold quality
tibial artery	UBERON:0007610	97.24	gold quality
skin of abdomen	UBERON:0001416	97.01	gold quality
lower esophagus muscularis layer	UBERON:0035833	96.96	gold quality
lower esophagus	UBERON:0013473	96.95	gold quality
gastrocnemius	UBERON:0001388	96.91	gold quality
left coronary artery	UBERON:0001626	96.73	gold quality
hindlimb stylopod muscle	UBERON:0004252	96.60	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	96.48	gold quality
coronary artery	UBERON:0001621	96.37	gold quality
right lung	UBERON:0002167	96.34	gold quality
muscle layer of sigmoid colon	UBERON:0035805	96.21	gold quality
body of uterus	UBERON:0009853	96.19	gold quality
muscle of leg	UBERON:0001383	96.16	gold quality
right frontal lobe	UBERON:0002810	96.02	gold quality
stromal cell of endometrium	CL:0002255	95.99	gold quality
tibial nerve	UBERON:0001323	95.97	gold quality
endocervix	UBERON:0000458	95.95	gold quality
apex of heart	UBERON:0002098	95.79	gold quality
mucosa of stomach	UBERON:0001199	95.78	gold quality
upper lobe of left lung	UBERON:0008952	95.66	gold quality
left uterine tube	UBERON:0001303	95.49	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	11.50
E-MTAB-9388	yes	6.23
E-GEOD-93593	no	271.92
E-CURD-112	no	2.63

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

101 targeting DLGAP4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-4500	99.99	72.72	2367
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-3148	99.97	75.06	6478
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-329-3P	99.91	66.56	1234
HSA-MIR-362-3P	99.91	66.38	1267
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-3941	99.86	70.54	2735
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-5010-3P	99.83	70.60	2357

Literature-anchored findings (GeneRIF, showing 7)

• Shows that an homologous rat protein can interact with nArgBP2, a novel neural member of the ponsin/ArgB/vinexin family. (PMID:10521485)
• Significant epigenetic remodelling of the DLGAP4 locus triggered by the t(8;20)(p12;q11.23) translocation and leading to dysregulation of DLGAP4 expression in affected carriers is reported. (PMID:24986922)
• Exosomal circ_DLGAP4 promotes diabetic kidney disease progression by sponging miR-143 and targeting ERBB3/NF-kappaB/MMP-2 axis. (PMID:33230102)
• DLGAP4 acts as an effective prognostic predictor for hepatocellular carcinoma and is closely related to tumour progression. (PMID:36396671)
• CircDLGAP4 induces autophagy and improves endothelial cell dysfunction in atherosclerosis by targeting PTPN4 with miR-134-5p. (PMID:37615249)
• CircDLGAP4 overexpression ameliorates neuronal injury in Parkinson’s disease by binding to EIF4A3 and increasing HMGA2 expression. (PMID:37822284)
• Includes the identification and characterization of an homologous protein in rat. (PMID:9115257)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	dlgap4b	ENSDARG00000012823
danio_rerio	dlgap4a	ENSDARG00000060849
mus_musculus	Dlgap4	ENSMUSG00000061689
rattus_norvegicus	Dlgap4	ENSRNOG00000020225

Paralogs (4): DLGAP3 (ENSG00000116544), DLGAP5 (ENSG00000126787), DLGAP1 (ENSG00000170579), DLGAP2 (ENSG00000198010)

Protein

Protein identifiers

Disks large-associated protein 4 — Q9Y2H0 (reviewed: Q9Y2H0)

Alternative names: PSD-95/SAP90-binding protein 4, SAP90/PSD-95-associated protein 4

All UniProt accessions (5): Q9Y2H0, A0A087WWE6, A0A087X246, A0A0B4J2C2, F8WF49

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in the molecular organization of synapses and neuronal cell signaling. Could be an adapter protein linking ion channel to the subsynaptic cytoskeleton. May induce enrichment of PSD-95/SAP90 at the plasma membrane.

Subunit / interactions. Interacts with DLG1 and DLG4/PSD-95.

Subcellular location. Membrane.

Similarity. Belongs to the SAPAP family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9Y2H0-2	1	yes
Q9Y2H0-1	2
Q9Y2H0-3	3

RefSeq proteins (14): NP_001035951, NP_001352550, NP_001375186, NP_001375189, NP_001375191, NP_001375194, NP_001375197, NP_001375200, NP_001375203, NP_001375204, NP_001375206, NP_001375207, NP_055717, NP_892118 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005026	SAPAP	Family

Pfam: PF03359

UniProt features (40 total): modified residue 17, compositionally biased region 9, region of interest 7, splice variant 3, sequence variant 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y2H0-F1	50.01	0.10

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (17): 206, 207, 291, 378, 381, 388, 405, 415, 421, 580, 581, 609, 611, 665, 744, 915, 973

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6794361	Neurexins and neuroligins

MSigDB gene sets: 238 (showing top): FXR_IR1_Q6, SHEPARD_BMYB_MORPHOLINO_UP, GGTGTGT_MIR329, LFA1_Q6, NIKOLSKY_BREAST_CANCER_20Q11_AMPLICON, HATADA_METHYLATED_IN_LUNG_CANCER_DN, SREBP1_02, GOBP_CELL_CELL_SIGNALING, BROWNE_HCMV_INFECTION_48HR_DN, GOBP_CELL_JUNCTION_ORGANIZATION, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, FREAC3_01, OCT1_03, GGARNTKYCCA_UNKNOWN, WTGAAAT_UNKNOWN

GO Biological Process (4): signaling (GO:0023052), modulation of chemical synaptic transmission (GO:0050804), regulation of synapse maturation (GO:0090128), modification of postsynaptic structure (GO:0099010)

GO Molecular Function (2): molecular adaptor activity (GO:0060090), protein binding (GO:0005515)

GO Cellular Component (7): plasma membrane (GO:0005886), neuromuscular junction (GO:0031594), glutamatergic synapse (GO:0098978), cholinergic synapse (GO:0098981), postsynaptic specialization (GO:0099572), membrane (GO:0016020), synapse (GO:0045202)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Protein-protein interactions at synapses	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
synapse	3
binding	2
regulation of biological process	1
chemical synaptic transmission	1
regulation of trans-synaptic signaling	1
regulation of developmental process	1
regulation of synapse organization	1
synapse maturation	1
modification of synaptic structure	1
molecular_function	1
membrane	1
cell periphery	1
organelle	1
postsynapse	1
cellular anatomical structure	1
cell junction	1

Protein interactions and networks

STRING

962 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DLGAP4	SHANK3	Q9BYB0	744
DLGAP4	DLG4	P78352	648
DLGAP4	SHANK2	Q9UPX8	577
DLGAP4	DLG2	Q15700	577
DLGAP4	GRIN2A	Q12879	549
DLGAP4	DNAH12	Q6ZR08	545
DLGAP4	DLG3	Q92796	532
DLGAP4	DNAH3	Q8TD57	505
DLGAP4	MPP3	Q13368	480
DLGAP4	GALNT17	Q6IS24	471
DLGAP4	SHANK1	Q9Y566	467
DLGAP4	DLGAP3	O95886	448
DLGAP4	ATP6V0A2	Q9Y487	446
DLGAP4	DLGAP2	Q9P1A6	427
DLGAP4	AK1	P00568	418

IntAct

167 interactions, top by confidence:

A	B	Type	Score
KCNJ2	KCNJ18	psi-mi:“MI:2364”(proximity)	0.660
DLGAP4	BIN1	psi-mi:“MI:0915”(physical association)	0.630
BIN1	DLGAP4	psi-mi:“MI:0915”(physical association)	0.630
DLGAP4	DLG4	psi-mi:“MI:0915”(physical association)	0.590
DLGAP4	LIN7A	psi-mi:“MI:0914”(association)	0.590
DLGAP4	CASK	psi-mi:“MI:0407”(direct interaction)	0.590
DLGAP4	DLG1	psi-mi:“MI:0407”(direct interaction)	0.590
DLGAP4	DLG3	psi-mi:“MI:0407”(direct interaction)	0.590
DLGAP4	DLG4	psi-mi:“MI:0407”(direct interaction)	0.590
DLGAP4	LIN7A	psi-mi:“MI:0407”(direct interaction)	0.590
DLGAP4	LIN7C	psi-mi:“MI:0407”(direct interaction)	0.590
MAGI3	DLGAP4	psi-mi:“MI:0407”(direct interaction)	0.590
DLGAP4	MPP7	psi-mi:“MI:0407”(direct interaction)	0.590
ZAR1L	BCL2L11	psi-mi:“MI:0914”(association)	0.530
NRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.480
DLGAP4	MAST2	psi-mi:“MI:0407”(direct interaction)	0.440
DLGAP4	SHANK1	psi-mi:“MI:0407”(direct interaction)	0.440
DLGAP4	SNX27	psi-mi:“MI:0407”(direct interaction)	0.440
SCRIB	DLGAP4	psi-mi:“MI:0407”(direct interaction)	0.440
DLGAP4	PDZK1	psi-mi:“MI:0407”(direct interaction)	0.440
DLGAP4	MAST1	psi-mi:“MI:0407”(direct interaction)	0.440
DLGAP4	NHERF2	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (89): BIN1 (Protein-peptide), DLGAP4 (Reconstituted Complex), DLGAP4 (Two-hybrid), DLGAP4 (Affinity Capture-RNA), DLGAP4 (Affinity Capture-RNA), DLGAP4 (Affinity Capture-MS), DLGAP4 (Affinity Capture-MS), DLGAP4 (Affinity Capture-MS), DLGAP4 (Affinity Capture-MS), DLGAP4 (Affinity Capture-MS), DLGAP4 (Affinity Capture-MS), DLGAP4 (Affinity Capture-MS), DLGAP4 (Affinity Capture-RNA), DLGAP4 (Proximity Label-MS), DLGAP4 (Proximity Label-MS)

ESM2 similar proteins: A0A1L8ER70, A1L253, A2AHC3, A5WUN7, B1AZP2, D4AEC2, O14490, P28290, P62024, P97836, P97839, Q148W8, Q14CH0, Q2KI52, Q2M3X8, Q3ZBW7, Q4KM62, Q4R2Y2, Q4R707, Q52KF3, Q5PQL8, Q5R3Z9, Q5RD34, Q5RJX2, Q5VUB5, Q5VZP5, Q5XII9, Q6GLU8, Q6NSV7, Q6P995, Q6PEI3, Q6RFY2, Q7T3E8, Q8BJ42, Q8BYK5, Q8C1B1, Q922B9, Q95X94, Q96BN6, Q96KR7

Diamond homologs: B1AZP2, O14490, O95886, P97836, P97837, P97838, P97839, Q15398, Q6PFD5, Q7K3L1, Q7ZYZ6, Q8BJ42, Q8K4R9, Q9D415, Q9P1A6, Q9Y2H0

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
DLGAP4	“up-regulates activity”	DLG4	binding
DLGAP4	“up-regulates activity”	SHANK1	relocalization
DLGAP4	“up-regulates activity”	SHANK2	relocalization
DLGAP4	“up-regulates activity”	SHANK3	relocalization

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 117 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Ras activation upon Ca2+ influx through NMDA receptor	7	50.0×	1e-08
Signaling by ERBB2 ECD mutants	5	42.0×	7e-06
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	6	38.9×	1e-06
Long-term potentiation	6	35.7×	1e-06
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	5	35.7×	1e-05
Unblocking of NMDA receptors, glutamate binding and activation	5	34.0×	2e-05
Negative regulation of NMDA receptor-mediated neuronal transmission	5	34.0×	2e-05
Downstream signal transduction	7	33.3×	2e-07

GO biological processes:

GO term	Partners	Fold	FDR
establishment or maintenance of epithelial cell apical/basal polarity	10	51.9×	2e-12
protein localization to synapse	6	41.0×	1e-06
receptor clustering	7	39.0×	2e-07
regulation of postsynaptic membrane neurotransmitter receptor levels	7	31.0×	7e-07
positive regulation of Rac protein signal transduction	5	28.9×	7e-05
ephrin receptor signaling pathway	5	15.3×	1e-03
Ras protein signal transduction	6	11.0×	1e-03
cell-cell adhesion	11	10.0×	2e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

145 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	117
Likely benign	11
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

3807 predictions. Top by Δscore:

Variant	Effect	Δscore
20:36432714:CAGGT:C	donor_loss	1.0000
20:36432715:AGGT:A	donor_loss	1.0000
20:36432716:GG:G	donor_loss	1.0000
20:36432718:T:A	donor_loss	1.0000
20:36436349:AG:A	donor_loss	1.0000
20:36436350:GG:G	donor_loss	1.0000
20:36436351:G:GA	donor_loss	1.0000
20:36436352:T:G	donor_loss	1.0000
20:36439742:A:AG	acceptor_gain	1.0000
20:36439750:CCA:C	acceptor_loss	1.0000
20:36439751:CAG:C	acceptor_loss	1.0000
20:36439752:A:AC	acceptor_loss	1.0000
20:36439753:G:GT	acceptor_gain	1.0000
20:36439753:GGA:G	acceptor_gain	1.0000
20:36439864:GCCAG:G	donor_gain	1.0000
20:36439866:CAGG:C	donor_loss	1.0000
20:36439868:GGTGA:G	donor_loss	1.0000
20:36446936:GA:G	donor_gain	1.0000
20:36496700:TGCA:T	acceptor_loss	1.0000
20:36496701:GCAG:G	acceptor_loss	1.0000
20:36496702:CA:C	acceptor_loss	1.0000
20:36497067:G:GG	donor_gain	1.0000
20:36500197:A:AG	acceptor_gain	1.0000
20:36500198:G:GG	acceptor_gain	1.0000
20:36500608:GAAG:G	donor_gain	1.0000
20:36500610:AGG:A	donor_loss	1.0000
20:36500612:GTGG:G	donor_loss	1.0000
20:36524240:T:A	acceptor_gain	1.0000
20:36524248:A:AG	acceptor_gain	1.0000
20:36524249:G:GG	acceptor_gain	1.0000

AlphaMissense

6493 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:36500510:G:A	G804D	1.000
20:36500518:T:C	F807L	1.000
20:36500519:T:C	F807S	1.000
20:36500520:C:A	F807L	1.000
20:36500520:C:G	F807L	1.000
20:36500528:T:C	L810P	1.000
20:36500531:T:C	L811P	1.000
20:36500560:T:A	W821R	1.000
20:36500560:T:C	W821R	1.000
20:36524283:C:A	A849D	1.000
20:36524292:T:C	L852P	1.000
20:36524316:T:C	F860S	1.000
20:36524328:G:A	C864Y	1.000
20:36524329:T:G	C864W	1.000
20:36525888:T:C	L881P	1.000
20:36525899:T:A	W885R	1.000
20:36525899:T:C	W885R	1.000
20:36525901:G:C	W885C	1.000
20:36525901:G:T	W885C	1.000
20:36525906:T:C	L887P	1.000
20:36525909:T:C	L888P	1.000
20:36525915:T:C	L890P	1.000
20:36525941:T:C	F899L	1.000
20:36525942:T:C	F899S	1.000
20:36525943:C:A	F899L	1.000
20:36525943:C:G	F899L	1.000
20:36525951:T:C	L902P	1.000
20:36525974:T:A	W910R	1.000
20:36525974:T:C	W910R	1.000
20:36525976:G:C	W910C	1.000

dbSNP variants (sampled 300 via entrez): RS1000007088 (20:36527805 C>A,G), RS1000029234 (20:36469772 T>A,C,G), RS1000033870 (20:36517010 C>T), RS1000043422 (20:36391209 G>A,T), RS1000087985 (20:36407434 G>A,T), RS1000095205 (20:36479780 G>A), RS1000110905 (20:36321178 G>T), RS1000115364 (20:36523134 G>A), RS1000125538 (20:36458042 G>A,C), RS1000148041 (20:36435056 C>G), RS1000224257 (20:36324559 C>T), RS1000237280 (20:36388387 C>T), RS1000245325 (20:36420965 ACT>A), RS1000246098 (20:36528145 T>C), RS1000255164 (20:36417569 C>T)

Disease associations

OMIM: gene MIM:616191 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST010152_5	Neuroblastoma or malignant cutaneous melanoma	6.000000e-06
GCST010204_77	Low density lipoprotein cholesterol levels	4.000000e-21

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004611	low density lipoprotein cholesterol measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, decreases expression, increases abundance	3
bisphenol A	affects expression, decreases expression	2
Acetaminophen	increases expression	2
Arsenic	affects methylation, decreases expression, increases abundance	2
Estradiol	affects cotreatment, increases expression, decreases expression	2
Cyclosporine	increases expression	2
FR900359	affects phosphorylation	1
bisphenol F	decreases expression, affects cotreatment	1
dicrotophos	increases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
kojic acid	increases expression	1
cobaltous chloride	increases expression	1
benzo(e)pyrene	affects methylation	1
aflatoxin B2	increases methylation	1
beta-methylcholine	affects expression	1
CGP 52608	affects binding, increases reaction	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
(+)-JQ1 compound	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Sunitinib	increases expression	1
Zoledronic Acid	decreases expression	1
Arsenic Trioxide	decreases expression	1
Vorinostat	decreases expression	1
Arbutin	increases expression	1
Atrazine	increases expression	1
Benzo(a)pyrene	affects methylation	1
Cadmium	decreases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.